Compare VIVS & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIVS | ISPC |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.8M |
| IPO Year | N/A | 2020 |
| Metric | VIVS | ISPC |
|---|---|---|
| Price | $1.31 | $3.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.6K | ★ 525.5K |
| Earning Date | 06-04-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,928,998.00 |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $0.10 |
| 52 Week High | $5.30 | $6.77 |
| Indicator | VIVS | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 47.60 |
| Support Level | $1.24 | $0.37 |
| Resistance Level | $1.88 | $6.77 |
| Average True Range (ATR) | 0.07 | 0.44 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 37.84 | 1.46 |
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.